Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy

Nikolaos Ioannou, Patrick R. Hagner, Matt Stokes, Anita K. Gandhi, Benedetta Apollonio, Mariam Fanous, Despoina Papazoglou, Lesley Ann Sutton, Richard Rosenquist, Rose Marie Amini, Hsiling Chiu, Antonia Lopez-Girona, Preethi Janardhanan, Farrukh T. Awan, Jeffrey Jones, Neil E. Kay, Tait D. Shanafelt, Martin S. Tallman, Kostas Stamatopoulos, Piers E.M. PattenAnna Vardi, Alan G. Ramsay

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Cancer treatment has been transformed by checkpoint blockade therapies, with the highest anti-tumor activity of anti-programmed death 1 (PD-1) antibody therapy seen in Hodgkin lymphoma. Disappointingly, response rates have been low in the non-Hodgkin lymphomas, with no activity seen in relapsed/refractory chronic lymphocytic leukemia (CLL) with PD-1 blockade. Thus, identifying more powerful combination therapy is required for these patients. Here, we preclinically demonstrate enhanced anti-CLL activity following combinational therapy with anti-PD-1 or anti-PD-1 ligand (PD-L1) and avadomide, a cereblon E3 ligase modulator (CELMoD). Avadomide induced type I and II interferon (IFN) signaling in patient T cells, triggering a feedforward cascade of reinvigorated T-cell responses. Immune modeling assays demonstrated that avadomide stimulated T-cell activation, chemokine expression, motility and lytic synapses with CLL cells, as well as IFN-inducible feedback inhibition through upregulation of PD-L1. Patient-derived xenograft tumors treated with avadomide were converted to CD8+ T cell-inflamed tumor microenvironments that responded to anti-PD-L1/PD-1-based combination therapy. Notably, clinical analyses showed increased PD-L1 expression on T cells, as well as intratumoral expression of chemokine signaling genes in B-cell malignancy patients receiving avadomide-based therapy. These data illustrate the importance of overcoming a low inflammatory T-cell state to successfully sensitize CLL to checkpoint blockade-based combination therapy. (Blood. 2021;137(2):216-231).

Original languageEnglish (US)
Pages (from-to)216-231
Number of pages16
JournalBlood
Volume137
Issue number2
DOIs
StatePublished - Jan 14 2021
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy'. Together they form a unique fingerprint.

Cite this